Bristol-Myers’ Abilify To Treat Irritabilty In Pediatric Patients With Autistic Disorder gets FDA Approval
Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co., Ltd. said that FDA has approved the supplemental New Drug Application or sNDA for Abilify for the treatment of irritability associated with autistic disorder in pediatric patients of ages 6 to 17 years. The approval of Abilify for the treatment of irritation in patients with autistic disorder in pediatric patients is based on data from two eight-week, randomized, double-blind, placebo-controlled, multi-center, Phase III studies.
- Abilify gets FDA approval for children
- Shire receives FDA nod for ADHD treatment
- FDA approval for Watson’s RAPAFLO
- FDA approval to Apidra(R) for diabetic children
